The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, with fewer bleeding complications. Venous thrombosis occurs when a blood clot lodges in the veins of the legs or lungs.
In a Phase 1 clinical study, researchers led by EPFL and their partners report that a new liver- and gut-targeted oral drug can safely lower triglycerides and other blood lipids. When we eat, our bodies convert extra calories, especially from carbs, sugar, fats, and alcohol, into molecules called “triglycerides”. Triglycerides are a form of fat
New options make care faster, safer, and more accessible At a glance: Tuberculosis remains one of the top infectious disease killers worldwide, a challenge amplified by drug-resistant forms of the disease. Now, in a major step forward, an international clinical trial has found three new safe and effective drug regimens for tuberculosis that is resistant to
First Drug Approved in New Class of Non-Opioid Pain Medicines; Agency Continues to Take Steps to Support New Approaches for Pain Management the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling
A team of international researchers has found a drug injected under the skin effectively treats asthma and chronic obstructive pulmonary disease and reduces the need for further treatment. Dr Sanjay Ramakrishnan, from UWA’s Medical School and the Institute for Respiratory Health, was lead author of the paper published in The Lancet Respiratory Medicine. “Asthma and chronic
A device that delivers direct stimulation to the brain was found to be a safe and effective means of treating depression at home, according to a new study by researchers at UTHealth Houston; the Institute of Psychiatry, Psychology & Neuroscience at King’s College London; and the University of East London. The research was published in Nature
Since the passing of Professor Emeritus Alan Mackay-Sim AM in 2023, his ground-breaking legacy research is about to be realised with a Phase I human clinical trial commencing to test the efficacy and safety of the transplantation of olfactory cell nerve bridges to treat chronic spinal cord injury. Griffith University researcher, Professor James St John,
A nonstatin therapy approved almost 3 years ago to treat low-density lipoprotein (LDL) cholesterol also cuts the risk of major cardiovascular events, especially heart attacks, according to data presented. Bempedoic acid, approved in February 2020 as Nexletol (Esperion), reduced by 13% the risk of a 4-part composite end point of major adverse cardiovascular events (MACE),
A new report has highlighted the consequences of misinformation, including loss of trust in public institutions, delayed action on pressing issues such as climate change, and the financial toll on healthcare services during the COVID-19 pandemic. The ‘Fault Lines’ report involved a panel of international experts, including leading cognitive scientist Professor Stephan Lewandowsky, from the University of
Thousands of people experiencing the debilitating symptoms of long covid are traveling abroad to seek costly but unproven treatments such as “blood washing”, according to an investigation carried out by The BMJ and ITV News released today. Patients are traveling to private clinics in Cyprus, Germany and Switzerland for apheresis – a blood-filtering treatment normally
